Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | SUCNR1 | Q9BXA5 | 16/20 | 0.46 |
| ▸ | OXGR1 | Q96P68 | 3/20 | 0.44 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29797374 | 0.86 | SUCNR1 (0.45) | SUCNR1OXGR1PDE10A | |
| SCHEMBL20153361 | 0.86 | SUCNR1 (0.45) | SUCNR1OXGR1PDE10A | |
| SCHEMBL276117 | 0.79 | SUCNR1 (0.50) | SUCNR1OXGR1PDE10A | |
| SCHEMBL6129289 | 0.79 | KCNH2 (0.55) | L3MBTL1SUCNR1OXGR1PDE10A | |
| SCHEMBL6899530 | 0.79 | SUCNR1 (0.47) | SUCNR1OXGR1PDE10A | |
| SCHEMBL20517681 | 0.78 | SUCNR1 (0.49) | SUCNR1OXGR1PDE10A | |
| SCHEMBL12895009 | 0.76 | PDE10A (0.49) | SUCNR1OXGR1PDE10A | |
| SCHEMBL30930276 | 0.76 | SUCNR1 (0.50) | SUCNR1OXGR1PDE10A | |
| SCHEMBL20481012 | 0.75 | SUCNR1 (0.47) | SUCNR1OXGR1PDE10A | |
| SCHEMBL23083184 | 0.75 | PDE10A (0.49) | SUCNR1OXGR1PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7119098-B2 | Heteroarylakanoic acids as intergrin receptor antagonists | PHARMACIA CORPORATION (US) | 2006-10-10 | — | — | US | disclosed |
| US-6933304-B2 | Heteroarylalkanoic acids as integrin receptor antagonists | PHARMACIA CORPORATION (US) | 2005-08-23 | — | — | US | disclosed |
| WO-2004058254-A1 | HETEROARYLALKANOIC ACIDS AS INTEGRIN RECEPTOR ANTAGONISTS | PHARMACIA CORPORATION (US) | 2004-07-15 | — | — | WO | disclosed |
| US-20040092497-A1 | Heteroarylakanoic acids as intergrin receptor antagonists | PHARMACIA CORPORATION | 2004-05-13 | — | — | US | disclosed |
| US-20020133023-A1 | Heteroarylalkanoic acids as integrin receptor antagonists | PHARMACIA CORPORATION | 2002-09-19 | — | — | US | disclosed |
| US-6268378-B1 | TREATING AND PREVENTING OSTEOPOROSIS, AND INHIBITING VASCULAR RESTENOSIS, DIABETIC RETINOPATHY, MACULAR DEGENERATION, ANGIOGENESIS, ATHEROSCLEROSIS, INFLAMMATION, VIRAL DISEASE, AND TUMOR GROWTH. | MERCK & CO., INC. | 2001-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020133023-A1 | Heteroarylalkanoic acids as integrin receptor antagonists | ITGA5, ITGA2B, ITGAV | ATM 4717/4885L3MBTL1 3816/4885SUCNR1 622/4885 |
| US-20040092497-A1 | Heteroarylakanoic acids as intergrin receptor antagonists | ITGA5, ITGB7, ITGA2B | ATM 4479/4885L3MBTL1 4617/4885SUCNR1 337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.